Vectura subsidiary Jagotec has entered into a development and license deal with Sandoz for its VR2081 combination therapy MDI for the treatment of asthma and COP, the company announced. Sandoz will pay $5 million up front and up to an additional $5 million in milestone payments, plus royalties on net sales, for US rights to the product. According to Vectura, … [Read more...] about Vectura licenses VR2081 MDI to Sandoz
Business
Opiant licenses Intravail technology from Aegis Therapeutics
Intranasal drug developer Opiant Pharmaceuticals has signed an exclusive global licensing deal with Aegis Therapeutics for use of Aegis’ Intravail absorption enhancers with Opiant's opioid antagonists, the company said. No financial terms were disclosed. Opiant (formerly Lightlake Therapeutics) licensed its intranasal naloxone formulation for the reversal of opioid … [Read more...] about Opiant licenses Intravail technology from Aegis Therapeutics
Spyryx Biosciences gets additional funding for development of SPX-101 for CF
According to Spyryx Biosciences, Cystic Fibrosis Foundation Therapeutics (CFFT) will increase a development award to Spyryx to provide a total of up to $5 million. The company said that it plans to use the funds for its HOPE-1 Phase 2 study of SPX-101, an inhaled SPLUNC1-derived peptide, in CF patients. Earlier this year, Spyryx announced positive top line data … [Read more...] about Spyryx Biosciences gets additional funding for development of SPX-101 for CF
Consort Medical doubles pre-tax profit over previous fiscal year
Consort Medical, parent company of device manufacturer Bespak and CDMO Aesica, has announced that its pre-tax profits for fiscal year 2017 almost doubled from FY 2016, rising from £11.3 million to £21.9 million. Bespak earnings before interest and taxes (EBIT) rose 3.9% and Aesica's EBIT rose 17.7%. Consort acquired Aesica in 2014, and in November 2015, the … [Read more...] about Consort Medical doubles pre-tax profit over previous fiscal year
Pulmatrix licenses kinase inhibitors from RespiVert
Inhaled drug developer Pulmatrix announced that it has licensed a portfolio of kinase inhibitors from Janssen Biotech subsidiary RespiVert that it plans to develop as inhaled therapies for respiratory diseases. According to a form filed with the US Securities and Exchange Commission (SEC), Pulmatrix will pay $1 million up front plus milestones ranging from $1-80 … [Read more...] about Pulmatrix licenses kinase inhibitors from RespiVert
Windtree partners with Lee’s Pharm for development of Aerosurf in Asia
Windtree Therapeutics has signed an agreement with Hong-Kong based Lee's Pharmaceutical Limited for the development and commercialization of Aerosurf and other KL4 surfactant products in a number of Asian countries, the company said. Lee's will also have the right to manufacture KL4 surfactants in China, but aerosol products are excluded from that license. In … [Read more...] about Windtree partners with Lee’s Pharm for development of Aerosurf in Asia
Grünenthal acquires global rights to Zomig nasal spray
The Grünenthal Group will acquire rights to all dosage forms of Zomig zolmitriptan for the treatment of migraines and cluster headaches, including Zomig nasal spray, from AstraZeneca for $200 million up front plus up to $102 million in future milestone payments the company said. The deal includes rights to market Zomig in all countries where it is approved except … [Read more...] about Grünenthal acquires global rights to Zomig nasal spray
Ascend Therapeutics to co-promote Sprix ketorolac nasal spray
Egalet Corporation has announced that Ascend Therapeutics will begin co-promoting Egalet's Sprix ketorolac tromethamine nasal spray to women's healthcare practitioners in the US in the third quarter of 2017 and will continue for at least two years. Financial terms of the deal were not disclosed. Sprix nasal spray was approved for the short term management of … [Read more...] about Ascend Therapeutics to co-promote Sprix ketorolac nasal spray
Albertsons to sell Lupin’s InspiraChamber exclusively in US
US grocer Albertsons will begin selling Lupin's InspiraChamber antistatic valved holding chamber exclusively in more than 1,700 pharmacies in 35 US states, Lupin has announced. The InspiraChamber spacer can be used with one of several pediatric face masks, including the SootherMask, which includes an opening for a child's pacifier. Lupin licensed the product from … [Read more...] about Albertsons to sell Lupin’s InspiraChamber exclusively in US
MannKind announces new CEO, Brazilian distribution deal for Afrezza
MannKind Corporation has announced the appointment of Michael Castagna as Chief Executive Officer, effective May 25, 2017. Castagna takes over the role from Matthew Pfeffer, who succeeded Alfred Mann as CEO in January 2016. Pfeffer had also served as CFO, a role that will now be filled on an interim basis by Rose Alinaya, who is currently the company's Senior VP … [Read more...] about MannKind announces new CEO, Brazilian distribution deal for Afrezza